GlassScriptPhysician profile
Thomas A Kaspar
NPI 1205810629
$99,934.71
in general payments reported to CMS, 2019-2025
20 companies · $54.34 in 2025
The $54.34 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $17K · 2021: $15K · 2022: $7,189 · 2023: $377 · 2024: $206 · 2025: $54.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $562 · Education: $75.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.80 |
| Education | $75.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $66,808.29 | 2019-2022 | |
| Pfizer INC. | $19,321.85 | 2019-2020 | |
| Gilead Sciences, INC. | $5,774.05 | 2019-2023 | |
| Janssen Products, LP | $4,029.33 | 2019-2022 | |
| Abbvie INC. | $688.36 | 2019-2025 | |
| Paratek Pharmaceuticals, INC. | $593.04 | 2019-2024 | Nuzyra |
| Janssen Biotech, INC. | $539.40 | 2019-2022 | |
| Emd Serono, INC. | $372.18 | 2019-2023 | Serostim |
| Theratechnologies INC. | $267.83 | 2019-2022 | |
| Insmed, INC. | $259.12 | 2020-2024 | Arikayce |
| Allergan, INC. | $257.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $246.24 | 2019-2025 | Delstrigo, Pifeltro, Dificid |
| Cipla USA INC. | $179.62 | 2022 | |
| Xellia Pharmaceuticals | $138.98 | 2019 | |
| Nabriva Therapeutics, Plc | $137.83 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $119.99 | 2022 | |
| Shionogi INC | $118.06 | 2021-2022 | |
| Janssen Scientific Affairs, LLC | $35.28 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $29.85 | 2019 | |
| Mayne Pharma Commercial LLC | $17.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kaspar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.